

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

Warnings and Precautions: Kidney toxicity was observed in animals who received viltolarsen. Although kidney toxicity was not observed in the clinical studies with VILTEPSO, the clinical experience with VILTEPSO is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VILTEPSO. Serum creatinine may not be a reliable measure of kidney function in DMD patients.

Please see Important Safety Information throughout. For additional information about VILTEPSO, see accompanying full Prescribing Information.

HOW TO INITIATE TREATMENT



Download the Patient Start Form at VILTEPSO.com Contact NS Support:

Phone: 833-NSSUPRT (833-677-8778) Fax: 888-212-0482

MAIL OR FAX THE COMPLETED FORM TO: NS Support Program, PO Box 29203, Phoenix, AZ 85038-9203, Phone: 833-NSSUPRT (833-677-8778), Fax: 888-212-0482 1. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE INFORMATION PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE INFORMATION PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE INFORMATION Complete all information requested below. PRIMARY CONTACT NAME D # GROUP # PHONE PREFIRED PHONE # PHONE POLCHOLOGIS PREADMONSHIP TO PATIENT SECONDARY D # GROUP # PHONE PREADMONSHIP TO PATIENT SECONDARY D # GROUP # PHONE Check if you are including a copy of the front and back of the patient's insurance card(s) or face sheet. 3. PHYSICIAN INFORMATION NAME First List) ADDRESS SAITE # CITY STATE TAX D # (optional) PHONE FAX EMAIL 4. PREFERRED SITE OF CARE (OPTIONAL) Check all that apply. Hoppid Cinc Hone Indusion Physician's Office Other Needs Site of Care Identification PREFERRED PROVIDER(s) (if Available) 5. PHYSICIAN DECLARATION NA physician's Signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (1) the travely is medically necessary and in the best interest of the patient dentified above; (2) the patient is appropriately indicated for GT. 01 Declarem macular depletophy, and (5) have obtained and provide any consent required under federal and state law for the release and use of the patient's information on his from to NS Pharma, it.e., (as defined on page 2 of this form, for the patient to not be NF Pharma, it.e., (as defined on page 2 of this form, for the patient on the form). PATENTI/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. PATENTI/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (6 OVER 16) SIGNATURE DATE TO PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION DATE TO PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (6 OVER 16) PRINT NAME DATE TO PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (6 OVER 16)	NE Support	Patient	t Start Form		MAIL or FAX completed Start Form to NS Suppor
1. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE INFORMATION PATIENT MAME (First, ML List)		MAIL OR FAX	THE COMPLETED FORM TO):	
PATENT MANE (First, MI, Last)	NS Support Program, Po	O Box 29203, Phoenix, AZ 85	6038-9203, Phone: 833-NSSUPR	T (833-677-877	8), Fax: 888-212-0482
ADDRESS CTTY STATE ZP PRIMARY CONTACT NAME RELATIONSHIP TO PATIENT Home Cell 0 2. INSURANCE INFORMATION Complete all information requested below. PRIMARY D # GROUP # PHONE POLICHICLDER RELATIONSHIP TO PATIENT SECONDARY D # GROUP # PHONE POLICHICLDER RELATIONSHIP TO PATIENT SECONDARY D # GROUP # PHONE POLICHICLDER RELATIONSHIP TO PATIENT Check if you are including a copy of the front and back of the patient's insurance card(s) or face sheet. 3. PHYSICIAN INFORMATION NAME (First, Last) FACULTY NAME ADDRESS SUITE # CITY STATE ZP PHONE FAX EMAL 4. PREFERRED SITE OF CARE (OPTIONAL) Check all that apply. PHONE FAX EMAL 5. PHYSICIAN DECLARATION A physician's signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for G71, OT Ducheme muscular dystrophy, and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to 18 Fharms, i.e. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispersing the therapy. PHYSICAN INME (Please Print) PHYSICAN INME (Pleas	1. PATIENT/PARENT/GUARDIA	AN/LEGAL REPRESENTATIVE			
PRIMARY CONTACT NAME	PATIENT NAME (First, MI, Last)				
EMAIL PREFERED PHONE # Home Cell 0 2. INSURANCE INFORMATION Complete all information requested below. PRIMARY 0 # GROUP # HONE POLCHOLDER RELATIONSHIP TO PATENT SECONDARY 0 # GROUP # HONE POLCHOLDER RELATIONSHIP TO PATENT	7.0511.00			STATE	ZIP
2. INSURANCE INFORMATION Complete all information requested below. PRIMARY					
Complete all information requested below. PRIMARY D # GROUP # PHONE POLICHOLDER RELATIONSHIP TO PATIENT SECONDARY D # GROUP # PHONE POLICHOLDER RELATIONSHIP TO PATIENT Check if you are including a copy of the front and back of the patient's insurance card(s) or face sheet. 3. PHYSICIAN INFORMATION NAME (First, Last) FACLITY NAME ADDRESS SUITE # CITY STATE ZIP TAX D # (optional) OFFICE CONTACT PHONE FAX EMAIL 4. PREFERRED SITE OF CARE (OPTIONAL) Check all that apply. Home Infusion Physician's Office Other Needs Site of Care Identification PREFERRED PROVOERING (If Available) 5. PHYSICIAN DECLARATION A physician's signature is required in order for NS Support to perform a benefits verification. By spining below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for GT 1.01 Duchemen muscular dystrophy, and (3) have obtained and provide any consent required under federal and state leav for the release and use of the patients information on this form to NS Pharma, Inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN MANE (Pease Print) PHYSICIAN SIGNATURE DATE 5. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (FOVER 18) SIGNATURE DATE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (FOVER 18) SIGNATURE DATE DATE	EMAIL		PREFERRED PHONE #		
PRIMARY D # GROUP # PHONE POLICHOLDER RELATIONSHIP TO PATIENT SECONDARY ID # GROUP # PHONE POLICHOLDER RELATIONSHIP TO PATIENT PHONE POLICHOLDER RELATIONSHIP TO PATIENT PHONE POLICHOLDER RELATIONSHIP TO PATIENT	2. INSURANCE INFORMATION	N			
POLICHOLDER RELATIONSHIP TO PATIENT SECONDARY ID # GROUP # PHONE POLICHOLDER RELATIONSHIP TO PATIENT Check if you are including a copy of the front and back of the patient's insurance card(s) or face sheet. 3. PHYSICIAN INFORMATION NAME (First, Last) FACILITY NAME ADDRESS SUITE # CITY STATE ZIP TAX ID # (optional) OFFICE CONTACT PHONE FAX EMAIL 4. PREFERRED SITE OF CARE (OPTIONAL) Check all that apply. Hospital Clinic Home Infusion Physician's Office Other Needs Site of Care Identification PREFERRED PROVIDER(s) (if Available) 5. PHYSICIAN DECLARATION A physician's signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for G71 Of Duchenne muscular dystrophy; and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN IMME (Please Print) PHYSICIAN IMME (Please Print) PHYSICIAN IMME (Please Print) PHYSICIAN ISBNATURE DATE A PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 16) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 16) SIGNATURE DATE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 16) SIGNATURE DATE DATE					
SECONDARY					
POLICHOLDER RELATIONSHIP TO PATIENT Check if you are including a copy of the front and back of the patient's insurance card(s) or face sheet. 3. PHYSICIAN INFORMATION NAME (First, Last)					
Check if you are including a copy of the front and back of the patient's insurance card(s) or face sheet. 3. PHYSICIAN INFORMATION NAME (First, Last)					
3. PHYSICIAN INFORMATION NAME (First, Let)					
NMIE (First, Last)	☐ Check if you are including a	copy of the front and back of the	e patient's insurance card(s) or face	e sheet.	
ADDRESS SUITE # CITY STATE ZIP PHONE FAX EMAIL 4. PREFERRED SITE OF CARE (OPTIONAL) Check all that apply. Hospital Clinic Home Infusion Physician's Office Other Needs Site of Care Identification PREFERRED PROVIDER(s) (if Available) 5. PHYSICIAN DECLARATION A physician's signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for G71.01 Ducheme muscular dystrophy, and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, Inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN NAME (Please Print) PHYSICIAN ISONAL NAME (Please Print) PHYSICIAN ISONAL THE PHYSICIAN ISONAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardan/Legal Representative Authorization on page 2 of this form), supporting the access program as indication the Patient/Legal Caerdina Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME	3. PHYSICIAN INFORMATION				
PHONE	NAME (First, Last)		FACILITY NAME		
PHONE	ADDRESS	SUITE #			
4. PREFERRED SITE OF CARE (OPTIONAL) Check all that apply. Hospital Civil Home Infusion Physician's Office Other Needs Site of Care Identification PREFERRED PROVIDER(s) (If Available) 5. PHYSICIAN DECLARATION A physician's signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for G71.01 Duchemen muscular dystrophy; and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN MAME (Please Print) PHYSICIAN SIGNATURE				OFFICE CONTACT	
Check all that apply. Hospital Clinic Home Infusion Physician's Office Other Needs Site of Care Identification PREFERRED PROVIDER(s) (if Available)	PHONE	FAX	EMAIL		
Hospital Clinic Home Infusion Physician's Office Other Needs Site of Care Identification	4. PREFERRED SITE OF CARE	(OPTIONAL)			
PREFERRED PROVIDEN(s) (If Available) 5. PHYSICIAN DECLARATION A physician's signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for G71.01 Duchenne muscular dystrophy; and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN MAME (Please Print) PHYSICIAN SIGNATURE 6. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardiant_egal Representative Authorization on page 2 of this form, for the patient to the NS Support Program, and to release the patient's Protected Health Information to NS Pharma, inc. (as defined on page 2 of this form), supporting the access program as indica on the Patient/Legal Guardian Authorization. PATIENT/PARENT/GUARDIANALEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE DATE PATIENT/PARENT/GUARDIANALEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME	Check all that apply.				
S. PHYSICIAN DECLARATION A physician's signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (I) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for 671.01 Duchenne muscular dystrophy, and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN NAME (Please Print) PHYSICIAN SIGNATURE DATE 6. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardian/Legal Representative Authorization on page 2 of this form, for the patient to participate in the NS support Program, and to release the patient's Protected Health Information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indice on the Patient/Legal Claudrian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME	☐ Hospital Clinic ☐ Home Infusion ☐	Physician's Office Other Needs	Site of Care Identification		
A physician's signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for G71.01 Duchenne muscular dystrophy; and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN MAME (Please Print) PHYSICIAN SIGNATURE DATE 6. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patients' signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardiant_egal Representative Authorization on page 2 of this form, for the patient to periodicale in the NS Support Program, and to release the patient's Protected Health information to NS Pharma, inc. (as defined on page 2 of this form), supporting the access program as indica on the Patient/Legal Guardian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME	PREFERRED PROVIDER(s) (If Available)				
A physician's signature is required in order for NS Support to perform a benefits verification. By signing below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for G71.01 Duchenne muscular dystrophy; and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN MAME (Please Print) PHYSICIAN SIGNATURE DATE 6. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patients' signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardiant_egal Representative Authorization on page 2 of this form, for the patient to periodicale in the NS Support Program, and to release the patient's Protected Health information to NS Pharma, inc. (as defined on page 2 of this form), supporting the access program as indica on the Patient/Legal Guardian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME	5 PHYSICIAN DECLAPATION				
By signing below, I certify that (1) the therapy is medically necessary and in the best interest of the patient identified above; (2) the patient is appropriately indicated for G71.01 Duchenne muscular dystrophy; and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, Inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSICIAN NAME (Please Print) PHYSICIAN INAME (Please Print) DATE 6. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardan/Legal Representative Authorization on page 2 of this form, for the patient to participate in the NS Support Program, and to release the patient's Protected Health information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indica on the Patient/Legal Guardan Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME			formation the section of the section		
Duchenne muscular dystrophy; and (3) I have obtained and provide any consent required under federal and state law for the release and use of the patient's information on this form to NS Pharma, inc. and its agents, including its commercial and field-based teams, for purposes of benefits verification and coordination of dispensing the therapy. PHYSIGIAN SIGNATURE DATE 6. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardian/Legal Representative Authorization on page 2 of this form, for the patient to participate in the NS support Program, and to release the patient's Protected Health Information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indica on the Patient/Legal Guardian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME				o. (9) the notiont is a	aprapriataly indicated for C71 01
PHYSICIAN NAME (Please Print) PHYSICIAN NAME (Please Print) PHYSICIAN SIGNATURE DATE G. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardian/Legal Representative Authorization on page 2 of this form, for the patient to participate in the NS Support Program, and to release the patient's Protected Health information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indice on the Patient/Legal Guardian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE DATE					
C. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME DATE ODATE	form to NS Pharma, Inc. and its agents,	including its commercial and field-bas	ed teams, for purposes of benefits verification	on and coordination o	f dispensing the therapy.
6. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE AUTHORIZATION NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardiant_egal Representative Authorization on page 2 of this form, for the patient by participate in the NS Support Program, and to release the patient's Protected Health Information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indicated the Information of NS Pharma, Inc. (as defined on page 2 of this form), supporting the Authorization.	PHYSICIAN NAME (Please Print)				
NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardian/Legal Representative Authorization on page 2 of this form, for the patient to participate in the NS support Program, and to release the patient's Protected Health Information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indice on the Patient/Legal Claudian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME					DATE
NS Support will contact the patient if physician is unable to obtain patient's signature. By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardian/Legal Representative Authorization on page 2 of this form, for the patient to participate in the NS support Program, and to release the patient's Protected Health Information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indice on the Patient/Legal Guardian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 16) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME.	PHYSICIAN SIGNATURE				
By signing below, I certify and acknowledge that I have read, understand, and agree to the Patient/Parent/Guardian/Legal Representative Authorization on page 2 of this form, for the patient to participate in the NS support Program, and to release the patient's Protected Health Information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indice on the Patient/Legal Claudian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME.		AN/LEGAL REPRESENTATIVE	AUTHORIZATION		
participate in the NS Support Program, and to release the patient's Protected Health Information to NS Pharma, Inc. (as defined on page 2 of this form), supporting the access program as indice on the Patient/Legal Guardian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) SIGNATURE DATE PATIENT/PARENT/GUARDIAN/LEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME	6. PATIENT/PARENT/GUARDIA				
PATIENT/PARENT/GUARDIANLEGAL REPRESENTATIVE (IF OVER 18) PRINT NAME	6. PATIENT/PARENT/GUARDIA NS Support will contact the pat	tient if physician is unable to ob	otain patient's signature.	tive Authorization on na	soe 2 of this form, for the natient to
	6. PATIENT/PARENT/GUARDIA NS Support will contact the pat By signing below, I certify and acknowledge participate in the NS Support Program, and	tient if physician is unable to ob e that I have read, understand, and agree t to release the patient's Protected Health Ir	otain patient's signature. o the Patient/Parent/Guardian/Legal Representa		
RELATIONSHIP TO PATIENT	6. PATIENT/PARENT/GUARDI. NS Support will contact the pat By signing below, I certify and acknowledge participate in the NS Support Program, and on the Patient/Legal Guardian Authorization	tient if physician is unable to ol e that I have read, understand, and agree t to release the patient's Protected Health In n.	otain patient's signature. o the Patient/Parent/Guardian/Legal Representa nformation to NS Pharma, Inc. (as defined on pa	ge 2 of this form), supp	orting the access program as indicate
	6. PATIENT/PARENT/GUARDIANS Support will contact the pat By signing below, I certify and acknowledgy participate in the NS Support Program, and on the Patient/Legal Guardian Authorization. PATIENT/PARENT/GUARDIAN/LEGAL R	tient if physician is unable to ol e that I have read, understand, and agree to to release the patient's Protected Health In. b.	otain patient's signature. to the Patient/Parent/Guardian/Legal Representanformation to NS Pharma, Inc. (as defined on pa	ge 2 of this form), supp	orting the access program as indicate

Important Safety Information

Warnings and Precautions (continued): Serum cystatin C, urine dipstick, and urine proteinto-creatinine ratio should be measured before starting VILTEPSO. Consider also measuring glomerular filtration rate before starting VILTEPSO. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months.

DOSING



VILTEPSO is given as an 80-mg/kg weekly intravenous (IV) infusion¹

 VILTEPSO can be administered using either a peripheral or central venous catheter





Calculate the appropriate dose of VILTEPSO based on patient weight1

Calculate the dose based on the dose of 80 mg/kg

80 mg/kg × patient's weight patient's weight and the recommended (in kg) = total dose of VILTEPSO (in mg) needed each week

> For example, a 35-kg child will need 2800 mg of VILTEPSO $(35 \text{ kg} \times 80 \text{ mg/kg})$

Calculate the volume needed based on the concentration in a single-dose 50-mg/mL vial

[80 mg/kg × patient's weight in kg] ÷ 50 mg/mL = volume of VILTEPSO (in mL) needed

> For example, a 35-kg child will need 56 mL of VILTEPSO $(35 \text{ kg} \times 80 \text{ mg/kg} \div 50 \text{ mg/mL})$

Note: If the volume of required VILTEPSO is less than 100 mL, dilution in 0.9% sodium chloride for injection, USP, is required such that the total volume in the infusion bag is 100 mL.

PLEASE SEE THE WEEKLY DOSING CHARTS FOR ODD BODY WEIGHTS-BASED CALCULATIONS ON THE NEXT PAGE



USP=United States Pharmacopeia.

Please see Important Safety Information throughout. For additional information about VILTEPSO, see accompanying full **Prescribing Information.**



2

WEEKLY DOSING CHART¹

Only odd kg body weight provided for illustrative purposes.

Body weight (kg)	Body weight (lb)	Total VILTEPSO dose (mg)	Theoretical number of vials required (vial)	Whole number of vials required (vial)	Volume of saline retained in infusion bag* (mL)	Volume of VILTEPSO injected into infusion bag (mL)	Total volume of VILTEPSO solution in infusion bag (mL)
15.0	33.0	1200	4.8	5	76.0	24.0	100.0
17.0	37.4	1360	5.4	6	72.8	27.2	100.0
19.0	41.8	1520	6.1	7	69.6	30.4	100.0
21.0	46.2	1680	6.7	7	66.4	33.6	100.0
23.0	50.6	1840	7.4	8	63.2	36.8	100.0
25.0	55.0	2000	8.0	8	60.0	40.0	100.0
27.0	59.4	2160	8.6	9	56.8	43.2	100.0
29.0	63.8	2320	9.3	10	53.6	46.4	100.0
31.0	68.2	2480	9.9	10	50.4	49.6	100.0
33.0	72.6	2640	10.6	11	47.2	52.8	100.0
35.0	77.0	2800	11.2	12	44.0	56.0	100.0
37.0	81.4	2960	11.8	12	40.8	59.2	100.0
39.0	85.8	3120	12.5	13	37.6	62.4	100.0
41.0	90.2	3280	13.1	14	34.4	65.6	100.0
43.0	94.6	3440	13.8	14	31.2	68.8	100.0
45.0	99.0	3600	14.4	15	28.0	72.0	100.0
47.0	103.4	3760	15.0 [†]	16	24.8	75.2	100.0
49.0	107.8	3920	15.7	16	21.6	78.4	100.0
51.0	112.2	4080	16.3	17	18.4	81.6	100.0
53.0	116.6	4240	17.0	17	15.2	84.8	100.0
55.0	121.0	4400	17.6	18	12.0	88.0	100.0
57.0	125.4	4560	18.2	19	8.8	91.2	100.0
59.0	129.8	4720	18.9	19	5.6	94.4	100.0
61.0	134.2	4880	19.5	20	2.4	97.6	100.0
63.0	138.6	5040	20.2	21	-	100.8	100.8
65.0	143.0	5200	20.8	21	-	104.0	104.0
67.0	147.4	5360	21.4	22	-	107.2	107.2
69.0	151.8	5520	22.1	23	-	110.4	110.4



When less than 100 mL of VILTEPSO is required:

- 1. Withdraw from the 100-mL infusion bag a volume of 0.9% sodium chloride for injection, USP, equivalent to the calculated volume of VILTEPSO solution that will be added.
- 2. Withdraw the calculated volume of VILTEPSO solution from the appropriate number of vials, and inject into the infusion bag, such that the total volume in the bag is 100 mL.

When 100 mL or more of VILTEPSO is required:

Withdraw the calculated volume of VILTEPSO solution from the appropriate number of vials, and inject into an empty infusion bag. Further dilution is not required if the volume of VILTEPSO is 100 mL or more.

Please see Important Safety Information throughout. For additional information about VILTEPSO, see accompanying full Prescribing Information.



^{*}If volume of VILTEPSO required is <100 mL, dilution in 0.9% sodium chloride for injection, USP, is required such that the total volume in the infusion bag is 100 mL. If the volume of VILTEPSO to be infused is ≥100 mL, dilution is not required.

[†]The actual number of theoretical vials required is 15.04.

PREPARATION AND ADMINISTRATION



VILTEPSO is supplied in single-dose (250-mg/5-mL) vials in a clear, colorless, preservative-free solution¹

- Visually inspect each vial. Do not use if the solution in the vials is discolored or particulate matter is present
- Allow the vials to warm to room temperature
- Mix the contents gently by inverting 2 to 3 times. Do not shake



Prepare the VILTEPSO solution for infusion using aseptic technique¹

If **less than 100 mL** of VILTEPSO is required:

- 1 Withdraw the calculated volume of VILTEPSO from the appropriate number of vials
- From a 100-mL infusion bag of 0.9% sodium chloride for injection, USP, withdraw a volume that is equivalent to the calculated volume of VILTEPSO
- 3 Inject VILTEPSO into the infusion bag
- 4 Visually inspect the infusion bag for particulates
- Gently invert the infusion bag to ensure equal distribution. Do not shake
- 6 Discard unused VILTEPSO

If **100 mL or more** of VILTEPSO is required, no additional dilution with 0.9% sodium chloride for injection, USP is required, and the required amount of VILTEPSO should be placed into an empty infusion bag. Visually inspect the infusion bag for particulates. Gently invert the infusion bag.



Selecting a comfortable needle size may help reduce injection discomfort^{2,3}



It should take 60 minutes to complete IV infusion of VILTEPSO¹

- Begin infusion as soon as possible—no more than 5 hours after preparation—and complete within 6 hours of preparation if diluted solution is stored at 20° C to 26° C (68° F to 79° F)
- Do not mix other medications with VILTEPSO or infuse other medications concomitantly via the same IV access line
- Flush the IV access line with 0.9% sodium chloride for injection, USP, after infusion





If injection site reaction or post-infusion low-grade fever occurs, patients may be managed on-site or at home with appropriate management techniques, including⁴:

- Over-the-counter pain relievers
- Antihistamines
- Antipyretics
- Cold compresses

Important Safety Information

Warnings and Precautions (continued): Urine should be free of excreted VILTEPSO for monitoring of urine protein. Obtain urine either prior to VILTEPSO infusion, or at least 48 hours after the most recent infusion. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, which has the potential to generate a false positive result due to cross reaction with any VILTEPSO in the urine. If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

Please see Important Safety Information throughout. For additional information about VILTEPSO, see accompanying full Prescribing Information.



VILTEPSO offers a choice of treatment location—at home or at a treatment center



VILTEPSO is given as an 80-mg/kg weekly IV infusion¹



The **appropriate dose**of VILTEPSO is calculated
based upon **patient weight**,
at a recommended weekly
dosage of 80 mg/kg¹



VILTEPSO is infused for **60 minutes** by a healthcare professional, at home or at a treatment center¹

Download the Patient Start Form at **VILTEPSO.com** to get your patients initiated on treatment

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

Adverse Reactions: The most common adverse reactions include upper respiratory tract infection, injection site reaction, cough, and pyrexia.

Please see Important Safety Information throughout. For more information about VILTEPSO, see accompanying full Prescribing Information.

References: 1. Viltepso [prescribing information]. Paramus, NJ: NS Pharma, Inc.; 2021. **2.** Gill HS, Prausnitz MR. Does needle size matter? *J Diabetes Sci Technol*. 2007;1(5):725-729. **3.** Aronson R. The role of comfort and discomfort in insulin therapy. *Diabetes Technol Ther*. 2012;14(8):741-747. **4.** Cole B. Injection-site reactions and how to manage them. *Pharmacy Times*. 2019;1(5):1-11.



© 2022 NS Pharma, Inc. All rights reserved. NS Pharma and the symbol for NS Pharma are registered trademarks of Nippon Shinyaku Co., Ltd. Viltepso is a registered trademark of Nippon Shinyaku Co., Ltd. The NS Support logo is a trademark of NS Pharma, Inc. 01/22 US-NS65C-0829

